The purpose of patent law is to provide a monopoly to the inventor for a limited period of time to encourage invention and innovation, to see that innovation ultimately serves society's interests. However, in the pharmaceutical sector this balance takes on a special meaning, as the longer a patent is protected, the more likely a medicine is to be unavailable and more expensive, or to be unavailable at all. Patent evergreening is a set of tactics that can be used by a patent holder to gain further term of monopoly rights by filing patents for relatively insignificant modifications of an existing product, even if they offer no significant therapeutic advantages. The key is to separate true incremental innovation from an effort to extend monopoly protection.
This balancing of these interests is evident in the Indian patent regime. India's generic pharmaceutical industry developed due to the Patents Act, 1970 which did not cover product patents for pharmaceutical substances. The duty under the TRIPS Agreement led to the inclusion of product patent protection in the amendment, culminating in the 2005 amendment. The introduction of Section 3(d) into Parliament was to avoid the patenting of new forms or derivatives of known substances unless they can be shown to provide improved therapeutic effects. It also renders ineligible for patenting any new use of substances already known.
Novartis AG v Union of India was a case that was focused on the interpretation of Section 3(d). Novartis has applied for patents on the beta crystalline form of imatinib mesylate which is linked to Gleevec. The Supreme Court decided that the claimed form was not the same as the form that enjoyed the benefits of the statutory requirement of improved therapeutic effect. The ruling set a high bar for secondary pharmaceutical patents and strengthened Section 3(d) as a protection against "evergreening”. Concurrently, the judgment acknowledged that member states have a certain degree of discretion as to what constitutes patentability under TRIPS. Even with this protection, Section 3(d) is difficult to interpret. The bill doesn't specify a specific quantifiable amount of increased efficacy; instead, patent examiners and courts will decide whether the standard is met. This flexibility can cause confusion for innovators in the pharmaceutical field, especially in cases of incremental changes that offer significant safety, stability, dosage, and therapeutic benefits. Another challenge is that there may be clinical evidence showing a therapeutic benefit after the filing deadline.
The Indian approach can also be compared markedly to the models of the United States and Europe which are being used today. Secondary patents are mainly dealt with in the United States through the doctrines of non-obviousness, double patenting and the Hatch-Waxman framework which promotes generic competition. European practice takes a different approach, allowing for protection of some new therapies, but not repeated monopolization of existing products. Evergreening is not restricted to Section 3(d). Under Section 107A (the Bolar exception), generic manufacturers can engage in activities prior to the expiration of a patent that are needed to obtain regulatory approval. This is a mechanism to avoid the unnecessary delay in generic market entry due to regulatory delays. European patent practice similarly permits protection for certain genuine pharmaceutical innovations, including particular formulations and therapeutic applications where the relevant legal requirements are satisfied. However, European systems also contain mechanisms designed to prevent repeated or unjustified extension of patent rights. The comparative experience demonstrates that there is no single universal solution to the problem of pharmaceutical evergreening. Different jurisdictions attempt to balance innovation and access through different combinations of patentability standards, examination practices, regulatory mechanisms, and generic competition.
The broader debate surrounding patent evergreening therefore raises a fundamental question: How much exclusivity is necessary to encourage pharmaceutical innovation, and at what point can additional exclusivity begin to undermine public access? There is no simple answer. Pharmaceutical research requires substantial financial investment and carries considerable scientific and commercial risk. Strong intellectual property protection can provide companies with incentives to invest in the development of new medicines. At the same time, excessively broad or repeatedly extended protection can limit competition and affect the affordability and availability of medicines, particularly in developing countries. For India, the objective should therefore not be to choose between innovation and access, but to design a legal framework in which the two can coexist. A clearer and more transparent approach to assessing enhanced efficacy, stronger patent examination and opposition mechanisms, greater regulatory coordination, and incentives for genuine incremental pharmaceutical research could help achieve this balance. Ultimately, patent law should reward real innovation rather than merely prolonged exclusivity. The Indian experience demonstrates that pharmaceutical patent policy has consequences far beyond the patent system itself. It affects researchers, pharmaceutical companies, generic manufacturers, healthcare institutions, and, most importantly, patients. The challenge for Indian patent law is thus to maintain an equilibrium in which inventors receive meaningful protection for genuine contributions while society retains access to affordable medicines. The future of pharmaceutical patent policy will depend on maintaining this delicate balance—ensuring that the patent system remains an engine of innovation without becoming a barrier to public health.
